Wonbiogen

원바이오젠KRX: 307280· Fiscal year 2025· wonbiogen.co.kr ↗

Average salary
Not disclosed
Employees
77
▲ 6.9% vs 2024
Average tenure
4 yrs

Reference: average annual pay in Healthcare & Pharma, South Korea: $31.4K (고용노동부 사업체노동력조사 2025 (KOSIS DT_118N_MON052), 2025). Official government wage statistics for the whole industry, not this company's pay. Definitions differ by country; see the source.

Workplace

Women's pay (men = 100)69
Women among staff41.6%
Contract staff0%

Recent official filings

Quick read

  • Headcount grew by 5 (6.9%) from 2024.
  • Revenue grew 15.8% year over year.
  • Revenue has grown two years in a row.
  • Operating margin was 22.5% in 2025.

Last 3 years

Revenue
$22.2M2023$22.8M2024$26.5M2025
Operating income
$5.3M2023$4.8M2024$5.9M2025

See the share price on Naver Finance ↗

Investor metrics

2025
Revenue per employee
$342.7K
Net profit per employee
$62.8K
Operating margin
22.5%
Net margin
18.3%
ROE
15.2%
Debt-to-equity
11.7%
Equity ratio
89.5%
Payout ratio
15.3%
Dividend per share
$0
Dividend yield (as disclosed)
2.2%

Per-employee figures use the company headcount, so they run high for groups with many subsidiaries. Not investment advice.

USD at ₩1,332.22 per $1 (2026-11-19, ExchangeRate-API)

Source: DART (Financial Supervisory Service, Korea)

Not investment advice. Figures come from public filings and may contain errors.